Education
About Us
Working with TipRanks
Follow Us
Heron Therapeutics (HRTX)
NASDAQ:HRTX
Earnings Data
Report Date
Mar 04, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.02Last Year’s EPS
0.02Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in key product lines such as ZYNRELEF and APONVIE, successful completion of financing, and the positive impact of new initiatives. However, challenges remain with declining SUSTOL sales, a decrease in gross margin, and a reported net loss due to debt extinguishment. Overall, the company appears to be on a positive trajectory but faces some financial challenges.Company Guidance
Successful Financing Completion
The company successfully completed its financing, resolving a significant overhang and allowing management to focus on commercial execution and product growth.
Revenue and Growth Metrics
Total net revenues for the quarter were $38.2 million, and $114.3 million year-to-date, with adjusted EBITDA of $1.5 million for the quarter and $9.5 million year-to-date.
Growth in ZYNRELEF and APONVIE Sales
ZYNRELEF net sales grew 49% year-over-year for Q3, while APONVIE net sales grew 173% in the same period.
Permanent J-Code for ZYNRELEF
The introduction of a permanent J-code for ZYNRELEF on October 1 is expected to streamline reimbursement and support broader adoption.
Positive Trends in Acute Care Portfolio
New initiatives, including CrossLink Ignite and the VAN, have resulted in increased demand and are expected to continue positively impacting sales.
HRTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HRTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 04, 2025 | $1.18 | $1.14 | -3.39% |
Aug 08, 2025 | $1.84 | $1.32 | -28.26% |
May 06, 2025 | $2.13 | $2.42 | +13.62% |
Feb 27, 2025 | $1.71 | $2.05 | +19.88% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Heron Therapeutics (HRTX) report earnings?
Heron Therapeutics (HRTX) is schdueled to report earning on Mar 04, 2026, Before Open (Confirmed).
What is Heron Therapeutics (HRTX) earnings time?
Heron Therapeutics (HRTX) earnings time is at Mar 04, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HRTX EPS forecast?
HRTX EPS forecast for the fiscal quarter 2025 (Q4) is -0.02.
